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Autologous Stem Cell Transplantation in Treatment of Aggressive Non-Hodgkin’s
Lymphoma
Hanneke C. Kluin-Nelemans
Department of Hematology, Groningen University Hospital, Groningen, the Netherlands
There is no doubt that autologous stem cell transplantation is useful for patients with relapsed aggressive non-Hodg-
kin’s lymphoma if they are responsive to the chemotherapy given before the transplantation. A small subset of patients
with primary refractory disease still profits from this high dose chemotherapy regimen, but only if chemosensitive and
if presenting with favorable risk factors at the moment of transplant eligibility. Autologous stem cell transplantation as
upfront first line therapy for patients with aggressive non-Hodgkin’s lymphoma does not contribute to a better out-
come, most certainly not if it concerns patients with a favorable risk profile. There is still some doubt whether there is
any place for autologous stem cell transplantation as first line therapy for patients with an unfavorable risk profile. Most
randomized studies do not show an advantage, but more data are needed to definitely assess the place for this therapy
option.
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Autologous stem cell transplantation is useful for
patients with relapsed aggressive non-Hodgkin’s lym-
phoma if they are responsive to the chemotherapy
given before the transplantation. But for which cate-
gory of patients with aggressive non-Hodgkin’s lym-
phoma is autologous stem cell transplantation the
best choice? The last two decades have shed more
light on this difficult question. As high dose therapy
was developed step-by-step, and always needs com-
parison with the so-called “gold” standard, some his-
tory is important.
Therapy through the Decades
Conventional Therapy in the 1960s and
1970s from First to Third Generation
Chemotherapy
Patients with advanced aggressive non-Hodg-
kin’s lymphoma can be effectively treated with multi-
agent chemotherapy. Although the majority of pa-
tients below the age of 65 will reach a complete re-
mission (CR) after CHOP-like (cyclophosphamide,
doxorubicin, vincristine, and prednisone) chemother-
apy, less than 50% will be finally cured (1). More in-
tensive chemotherapy regimens, such as MACOP-B
(methotrexate, doxorubicin, cyclophosphamide, vin-
cristine, prednisone, and bleomycin), ProMace-Cyta
BOM (prednisone, doxorubicin, cyclophosphamide,
etoposide, cytarabine, bleomycin, vincristine, metho-
trexate, leucovorin, and septra), or m-BACOD (me-
thotrexate, bleomycin, doxorubicin, cyclophospha-
mide, vincristine, and dexamethasone) generally yiel-
ded complete remission up to 80%, which is very
high, but were apparently based upon data from
highly selected patients with generally less unfavor-
able risk factors. Indeed, in a large randomized trial
no difference was found between those three inten-
sive chemotherapy regimens and classic CHOP (2).
Supra-high Dosed Chemotherapy:
Autologous Stem Cell Transplantation
In the mid 1980s, high dose chemotherapy fol-
lowed by autologous stem cell rescue became a ma-
ture therapy option, and appeared active for relapsing
and refractory non-Hodgkin’s lymphoma patients
(3-6). Obviously, dose escalation could cure some pa-
tients with conventional chemotherapy-resistant dis-
ease. In the following years, patient selection became
important to define which patients should be offered
autologous stem cell transplantation. It appeared that
the following selection criteria were important: a)
autologous stem cell transplantation as second line
treatment for truly relapsing patients vs primary re-
fractory patients; b) early (upfront) transplantation for
patients in their first line treatment vs transplantation
for patients at relapse; and c) upfront autologous stem
cell transplantation for patients with a favorable risk
profile according to the International Prognostic In-
dex (IPI) (7) vs an unfavorable IPI risk profile.
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Autologous Stem Cell Transplantation for
Patients in Relapse or Not Responding upon
Initial CHOP-like Therapy.
Philip et al (8) performed a large randomized
phase III trial, the PARMA trial, for patients with ag-
gressive non-Hodgkin’s lymphoma relapsing after a
documented complete remission. He showed con-
vincingly that autologous stem cell transplantation re-
sulted in a better progression free survival and overall
survival. It is important, however, to realize that many
patients were excluded from this trial because of strict
selection criteria, such as the absence of bone mar-
row infiltration or infiltration of the central nervous
system during relapse. Ever since these results were
published, autologous stem cell transplantation has
been considered standard for patients below the age
of 60-65 years, relapsing after CHOP-like chemother-
apy.
Recently, Vose et al (9) showed that autologous
stem cell transplantation could result in cure for a mi-
nority of patients who never achieved complete re-
mission after induction chemotherapy. The most im-
portant factor for a successful outcome is whether a
patient is still responsive to the second-line therapy
and hence shows so-called chemosensitivity (10,11).
Moreover, the age of the patient, the performance
score, the lactate dehydrogenase (LDH) level, and
stage of the disease, e.g., the IPI score at relapse, are
important criteria for the prediction if such a therapy
is justified for this category of patients (12).
Randomized Phase III Studies Incorporating
Autologous Stem Cell Transplantation as
First Line Therapy
In large overviews covering more than 1,200 pa-
tients, Goldstone (13) and Armitage (14) compared
the results from patients who underwent transplanta-
tion while in first complete remission, first partial re-
mission, second complete remission, or during re-
lapse/progressive disease. The analysis of these com-
piled data showed that this form of bone marrow ab-
lative therapy could result in long-term disease-free
survival in more than half of the patients receiving the
transplant at a time of minimal disease (e.g., during
first complete remission), early in the course of their
lymphoma. However, selection might have played a
major role in the outcome of these patients, because
none of them had been treated in randomized phase
III trials.
Therefore, aiming to improve the outcome in pa-
tients with aggressive non-Hodgkin’s lymphoma,
many groups initiated multicenter, phase III random-
ized trials comparing autologous stem cell transplan-
tation with some form of standard chemotherapy for
patients early in the phase of their disease. Most stud-
ies included patients aged 15-60 with a newly diag-
nosed stage II-IV aggressive non-Hodgkin’s lympho-
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Table 1. Overview of randomized trials with more than 100 patients incorporating early autologous stem cell transplantation for




















Verdonck et al (22)
286/69 76 all IPI no;
4 CHOP
TBI/cyclo 36 no difference in OS and DFS for patients in
PR after 3 CHOP
GELA LNH87-2,
Haioun et al (23)
881/464 76 all IPI yes;
6 CHOP-like
CVB 30 no difference in OS or DFS
GELA LNH87-2, with
2 or 3 risk factors (24)
451/236 69 unfavorable idem idem 96 high risk subset: ASCT arm superior for OS
and DFS
Italian NHLCSG,
Santini et al (25)
124/124 71 all IPI yes;
12 weeks VACOP-Bb
BEAM 42 no difference in OS, DFS or PFS; subset IPI
HI and high: auto-SCT arm better DFS, but
no difference in OS or PFS
Milan, single center,
Gianni et al (26)




55 high dose better DFS, no difference in OS
(P=0.09)
GELA, LNH94-3,
Gisselbrecht et al (11)
397/370 74 unfavorable no;
sequential high dose
BEAM or CVB 60 premature closure due to a high % failures
and relapses
EORTC 20901,
Kluin-Nelemans et al (27)
311/194 61 all IPI yes;
6 CHOP-like
BEAC 53 no difference in OS or FFP
German High Grade
Lymphoma Study Group,
Kaiser et al (28)
312/262 67 all IPI no;
3 CHOP-like
BEAM 12 no difference in OS, neither in the IPI unfa-
vorable subset
BNLI/Nordisk/ Australa-sian
Linch et al (29)
457/457 62 unfavorable no;
3 CHOP
BEAM 54 no difference in OS; only IPI high and H-I
patients
GOELAM,
Milpied et al (30)
207/197 81 all, except IPI
high risk
no;
2 CEEP, HD MTX
BEAM 46 ASCT better EFS outcome. OS difference
marginal. No IPI high risk patients included.
Subset analysis of favorable group: no differ-
ences; of intermediate high IPI subset: EFS
and OS better. Of note, at an earlier analysis
in 1998, both arms were equal (31).
aAbbreviations: IPI – International Prognostic Index; CHOP – cyclophosphamide, doxorubicin, vincristine, prednisolone; TBI – total body irradiation; OS – overall sur-
vival; DFS – disease free survival; PR – partial remission; LNH – lymphoma, non-Hodgkin; CVB – cyclophosphamide, etoposide (VP-16), BCNU (bischloroethyl
nitrosourea, or carmustine); NHLCSG – non-Hodgking’s lymphoma cooperative study group; ASCT – autologous stem cell transplantation; VACOP-B – etoposide,
doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; DHAP – dexamethasone, cytarabine, cisplatin; CR – complete remission; BEAM – BCNU,
etoposide, cytarabine, melphalan; PFS – progression-free survival; Bu – busulfan; EORTC – European Organization of Research and Treatment of Cancer; BEAC –
BCNU, etoposide, cytarabine, and cyclophosphamide; BNLI – British National Lymphoma Investigation; GOELAM – Groupe Ouest Est Leucemies Aigues
Myeloblastiques; FFP – free from progression ; H-I – high-intermediate; CEEP – cyclophosphamide, vindesine, etoposide, prednisone; HD MTX – high-dose
methotrexate; EFS – event-free survival.
bControl arm incorporated DHAP if no CR after VACOP-B.
cCross-over was allowed.
dTBI was replaced by mitoxantrone because of excessive toxicity.
ma. For elderly patients (65 years), high-dose che-
motherapy was, and still is, considered too toxic.
A selected summary of published randomized
trials incorporating autologous stem cell transplanta-
tion, and their data, we can conclude that thus far
most studies have not shown the advantage of auto-
logous stem cell transplantation over other forms of
therapy in patients with aggressive non-Hodgkin’s
lymphoma belonging to the IPI low and intermedi-
ate-low risk categories (Table 1). There are no conclu-
sive data for patients with an unfavorable risk profile
(IPI high and intermediate-high), since different stud-
ies found different outcomes in such patients after
autologous stem cell transplantation.
Statistics and Toxicity
Most studies have been designed to detect a 20%
difference or more in time to progression over 5 years
in favor of the autologous stem cell transplantation
therapy. For most groups, this difference seemed jus-
tified, assuming that any smaller difference would not
be clinically relevant in view of the expected toxicity
of the autologous stem cell transplantation arm. A
20% difference would nowadays be considered too
optimistic. Moreover, given the low autologous stem
cell transplantation-related short-term toxicity, found
in most studies (the combination of total body irradia-
tion and busulfan excluded), smaller differences
would also be of interest. Using very sophisticated
methods, the French Groupe d’Etude des Lympho-
mes de l’Adulte (GELA group) additionally analyzed
the quality of life of patients who had undergone
autologous stem cell transplantation (15). They dem-
onstrated that patients with transplants had more
months without symptoms and toxicity than the con-
trol group. The advantage was more pronounced in
high-risk patients (15). On the other hand, a Dutch
evaluation on quality of life based upon low numbers
of patients (6-13 per time point and per group) with
the autologous stem cell transplantation arm showed
that they had more complaints during the first 6
months, presumably due to the total body irradiation
regimen (16).
Presently, it is important to look at long-term tox-
icity as well. New data demonstrate an alarmingly
high incidence of secondary malignancies following
autologous stem cell transplantation procedures (17-
20). This should question the application of high-dose
chemotherapy in non-Hodgkin’s lymphoma patients
if the chances of improvement are not substantial.
Subgroup Analysis According to Risk Profiles
and Pathology
Patients with non-Hodgkin’s lymphoma, so-cal-
led aggressive lymphoma (formerly designated as
non-Hodgkin’s lymphoma of intermediate and some-
times high malignancy grade), fall into all kinds of risk
groups with highly different prognoses. Four risk
groups can be identified by IPI (7), an international
scoring model used at diagnosis for estimating the
chance to attain complete remission of aggressive
lymphoma by CHOP-like therapy. IPI is based on the
following parameters at diagnosis: age, performance
status, LDH level, stage of the disease, and number of
extranodal localizations. Moreover, pathology sub-
groups defined according to the World Health Orga-
nization’s classification (21) also discriminate sub-
groups with large differences in overall survival and
disease-free survival. Subset analyses on pathology
subgroups have not been performed as yet. A meta-
analysis will be needed to answer this question retro-
spectively. Moreover, the wish to incorporate anti-B
cell monoclonal antibodies in new studies will specif-
ically exclude patients with anaplastic large cell lym-
phoma or peripheral T cell lymphoma. It is clear that
most groups will not be able to perform on their own
phase III studies on subsets of patients with aggressive
non-Hodgkin’s lymphoma. Only large intergroup
randomized studies will be statistically powerful
enough to provide meaningful answers.
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